Clinical Trial Update: MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating safety of switching from intravenous to subcutaneous rituximab during first-line treatment for lymphoma shows completed status with p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Lymphoma, Non Hodgkin | Phase 3 | Status: COMPLETED | Results posted: 2018-07-05